Sternal ECG Patch Comparison Trial
Comparison of a Sternal ECG Patch With a Standard Recording System for Holter Monitoring
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand, 1142
- Auckland City Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Syncope of uncertain etiology or
- Pre-syncope of uncertain etiology or
- Palpitations of uncertain etiology or
- Management of known AF/SVT patients
Exclusion Criteria:
- Any dermatitis or infected skin over the sternum (Carnation patch) or left upper anterior thorax (Zio patch).
- A sternal or thoracic incision that extends under the patch within 3 months from the date of enrollment
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ECG signal quality
Time Frame: 24 hours of patient use, plus shipping and analysis time ~ 2 weeks
|
ECG signal quality = scoring the ability of each system to record electrical activity from the atrium (P-waves).
The Physician Event Committee will independently score the P-waves from all recordings, using the following scale: Excellent, Good, Fair, Poor, Non-existent.
Diagnostic yield will also be assessed.
|
24 hours of patient use, plus shipping and analysis time ~ 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device comfort
Time Frame: 24 hours
|
Secondary outcome measures will include Human Factors performance of the 2 systems, which will be scored and compared in the following areas and duration of patch adherence: skin irritation, comfort, contact and stability.
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jon Hunt, PhD, Bardy Diagnostics, Inc. (sponsor)
- Principal Investigator: Warren Smith, MBChB, Auckland City Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Unconsciousness
- Consciousness Disorders
- Atrial Fibrillation
- Tachycardia
- Syncope
- Tachycardia, Supraventricular
Other Study ID Numbers
Other Study ID Numbers
- 6147 (Other Identifier: University of Colorado CTRC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.